Background
Methods
Study population and data extracted
Statistical analysis
Results
Patient characteristics from SEER database
The optimal cutoff value for NLN count calculated by X-tile
LNs | No. | 5-year CCS | χ2 |
P value | LNs | No. | 5-year CCS | χ2 |
P value |
---|---|---|---|---|---|---|---|---|---|
≤0 | 72 | 51.8% | 41.745 | 0.000 | ≤12 | 3685 | 76.5% | 42.763 | 0.000 |
>0 | 5996 | 79.5% | >12 | 2383 | 83.3% | ||||
≤1 | 230 | 63.5% | 50.100 | 0.000 | ≤13 | 4022 | 76.9% | 38.747 | 0.000 |
>1 | 5838 | 79.7% | >13 | 2046 | 83.6% | ||||
≤2 | 444 | 68.2% | 44.132 | 0.000 | ≤14 | 4320 | 77.3% | 33.939 | 0.000 |
>2 | 5624 | 80.0% | >14 | 1748 | 83.7% | ||||
≤3 | 720 | 69.0% | 54.496 | 0.000 | ≤15 | 4585 | 77.3% | 36.435 | 0.000 |
>3 | 5348 | 80.5% | >15 | 1483 | 84.8% | ||||
≤4 | 1015 | 70.0% | 67.375 | 0.000 | ≤16 | 4822 | 77.6% | 33.037 | 0.000 |
>4 | 5053 | 81.0% | >16 | 1246 | 85.3% | ||||
≤5 | 1314 | 71.8% | 68.432 | 0.000 | ≤17 | 5013 | 72.8% | 27.827 | 0.000 |
>5 | 4754 | 81.2% | >17 | 1055 | 85.4% | ||||
≤6 | 1625 | 72.5% | 74.979 | 0.000 | ≤18 | 5177 | 78.0% | 23.546 | 0.000 |
>6 | 4443 | 81.6% | >18 | 891 | 85.5% | ||||
≤7 | 1974 | 73.5% | 74.302 | 0.000 | ≤19 | 5302 | 78.0% | 25.448 | 0.000 |
>7 | 4094 | 81.9% | >19 | 766 | 86.8% | ||||
≤8 | 2285 | 74.2% | 70.405 | 0.000 | ≤20 | 5422 | 78.2% | 25.257 | 0.000 |
>8 | 3783 | 82.1% | >20 | 646 | 87.2% | ||||
≤9 | 2613 | 74.3% | 78.060 | 0.000 | ≤21 | 5528 | 77.9% | 21.120 | 0.000 |
>9 | 3455 | 82.8% | >21 | 540 | 87.5% | ||||
≤10 | 2973 | 75.0% | 67.236 | 0.000 | ≤22 | 5606 | 78.4% | 21.730 | 0.000 |
>10 | 3095 | 83.1% | >22 | 462 | 88.0% | ||||
≤11 | 3320 | 75.6% | 57.663 | 0.000 | ≤23 | 5671 | 78.5% | 18.872 | 0.000 |
>11 | 2748 | 83.4% | >23 | 397 | 88.8% |
Characteristic | Total | NLN ≤ 9 | NLN > 9 |
P value | |
---|---|---|---|---|---|
6068 | 2613 | 3455 | |||
Follow up | Median (IQU) | 58 (42-81) months | |||
Year of diagnosis | 0.000 | ||||
2004–2007 | 3122 | 1553 | 1569 | ||
2008–2010 | 2946 | 1060 | 1886 | ||
Sex | 0.007 | ||||
Male | 3881 | 1625 | 2256 | ||
Female | 2187 | 988 | 1199 | ||
Age | 0.000 | ||||
<60 | 3368 | 1365 | 2003 | ||
≥60 | 2700 | 1248 | 1452 | ||
Race | 0.593 | ||||
White | 4927 | 2137 | 2790 | ||
Black | 511 | 214 | 297 | ||
Others | 630 | 262 | 368 | ||
Grade | 0.222 | ||||
Grade I/ II | 5098 | 2184 | 2914 | ||
Grade III/ IV | 970 | 429 | 541 | ||
Histologic type | 0.430 | ||||
Adenocarcinoma | 5517 | 2367 | 3150 | ||
Mucinous adenocarcinoma | 490 | 215 | 275 | ||
Signet ring cell carcinoma | 61 | 31 | 30 | ||
ypT stage | 386 | 189 | 197 | 0.062 | |
1 | 957 | 425 | 532 | ||
2 | 4306 | 1820 | 2486 | ||
3 | 419 | 179 | 240 | ||
4 | |||||
LNs dissected | 12.79 | 6.92 | 17.23 | 0.000 |
Impact of the NLN count on CSS in RC patients who received Pre-RT
Characteristic | 5-year CCS | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|
χ2 test |
P
| HR(95%CI) |
P
| ||
Year of diagnosis | 2.412 | 0.120 | NI | ||
2004–2007 | 78.4% | ||||
2008–2010 | 80.2% | ||||
Sex | 1.655 | 0.198 | NI | ||
Male | 29.5% | ||||
Female | 78.4% | ||||
Age | 21.805 | 0.000 | 0.000 | ||
< 60 | 81.3% | Ref | |||
≥ 60 | 76.4% | 0.777 (0.697 ~ 0.866) | 0.000 | ||
Race | 14.873 | 0.000 | 0.909 | ||
White | 79.5% | Ref | |||
Black | 72.7% | 1.129 (0.937 ~ 1.364) | 0.202 | ||
Others | 81.8% | 1.585 (1.246 ~ 2.017) | 0.000 | ||
Grade | 112.363 | 0.000 | 0.000 | ||
Grade I/ II | 81.5% | Ref | |||
Grade III/ IV | 66.9% | 0.596 (0.523 ~ 0.680) | 0.000 | ||
Histologic type | 81.128 | 0.000 | 0.000 | ||
Adenocarcinoma | 80.4% | Ref | |||
Mucinous adenocarcinoma | 69.2% | 0.412 (0.308 ~ 0.635) | 0.000 | ||
Signet ring cell carcinoma | 32.5% | 0.601 (0.408 ~ 0.885) | 0.010 | ||
ypT stage | 148.323 | 0.000 | 0.000 | ||
1 | 88.6% | Ref | |||
2 | 87.9% | 0.293 (0.212 ~ 0.405) | 0.000 | ||
3 | 77.9% | 0.303 (0.239 ~ 0.384) | 0.000 | ||
4 | 62.6% | 0.584 (0.494 ~ 0.692) | 0.000 | ||
LNs | 2.234 | 0.135 | NI | ||
≤ 12 | 78.5% | ||||
> 12 | 79.8% | ||||
NLN | 78.060 | 0.000 | 0.000 | ||
≤ 9 | 74.3% | Ref | |||
> 9 | 82.8% | 1.623 (1.457 ~ 1.809) | 0.000 |
Impact of the NLN count on CSS in RC patients based on each pathological grade
Characteristic | 5-year CCS | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|
χ2 test |
P
| HR(95%CI) |
P
| ||
Year of diagnosis | 6.324 | 0.012 | 0.035 | ||
2004–2007 | 87.9% | Ref | |||
2008–2010 | 92.2% | 1.609 (1.029 ~ 2.517) | 0.037 | ||
Sex | 1.238 | 0.266 | NI | ||
Male | 90.0% | ||||
Female | 89.3% | ||||
Age | 2.359 | 0.125 | NI | ||
< 60 | 91.3% | ||||
≥ 60 | 88.0% | ||||
Race | 6.222 | 0.045 | 0.053 | ||
White | 88.9% | Ref | |||
Black | 81.0% | 3.792 (1.201 ~ 11.968) | 0.023 | ||
Others | 98.9% | 4.392 (1.251 ~ 15.415) | 0.021 | ||
Grade | 0.483 | 0.487 | NI | ||
Grade I/ II | 90.0% | ||||
Grade III/ IV | 85.1% | ||||
Histologic type | 3.218 | 0.200 | NI | ||
Adenocarcinoma | 89.8% | ||||
Mucinous adenocarcinoma | 89.5% | ||||
Signet ring cell carcinoma | 50.0% | ||||
ypT stage | 0.001 | 0.972 | NI | ||
1 | 90.5% | ||||
2 | 89.4% | ||||
LNs | 9.401 | 0.002 | 0.284 | ||
≤ 12 | 87.8% | Ref | |||
> 12 | 93.4% | 1.702 (0.949 ~ 3.052) | 0.074 | ||
NLN | 7.080 | 0.008 | 0.600 | ||
≤ 9 | 87.6% | Ref | |||
> 9 | 91.6% | 1.128 (0.682 ~ 1.866) | 0.638 |
Characteristic | 5-year CCS | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|
χ2 test |
P
| HR(95%CI) |
P
| ||
Year of diagnosis | 0.255 | 0.614 | NI | ||
2004–2007 | 84.1% | ||||
2008–2010 | 84.7% | ||||
Sex | 1.414 | 0.234 | NI | ||
Male | 85.1% | ||||
Female | 83.0% | ||||
Age | 21.435 | 0.000 | 0.000 | ||
< 60 | 87.2% | Ref | |||
≥ 60 | 81.1% | 0.677 (0.566 ~ 0.810) | 0.000 | ||
Race | 1.812 | 0.404 | NI | ||
White | 84.6% | ||||
Black | 81.4% | ||||
Others | 84.4% | ||||
Grade | 24.552 | 0.000 | 0.000 | ||
Grade I/ II | 85.6% | Ref | |||
Grade III/ IV | 76.2% | 0.599 (0.479 ~ 0.748) | 0.000 | ||
Histologic type | 6.705 | 0.035 | 0.042 | ||
Adenocarcinoma | 85.0% | Ref | |||
Mucinous adenocarcinoma | 75.9% | 0.786 (0.249 ~ 2.481) | 0.682 | ||
Signet ring cell carcinoma | 71.6% | 1.103 (0.339 ~ 3.590) | 0.871 | ||
ypT stage | 21.301 | 0.000 | 0.000 | ||
3 | 85.4% | Ref | |||
4 | 73.2% | 0.591 (0.445 ~ 0.767) | 0.000 | ||
LNs | 9.648 | 0.002 | 0.892 | ||
≤ 12 | 82.5% | Ref | |||
> 12 | 86.7% | 0.983 (0.749 ~ 1.289) | 0.900 | ||
NLN | 20.806 | 0.000 | 0.002 | ||
≤ 9 | 80.9% | Ref | |||
> 9 | 86.5% | 1.520 (1.170 ~ 1.975) | 0.002 |
Characteristic | 5-year CCS | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|
χ2 test |
P
| HR(95%CI) |
P
| ||
Year of diagnosis | 0.038 | 0.846 | NI | ||
2004–2007 | 65.6% | ||||
2008–2010 | 67.0% | ||||
Sex | 0.026 | 0.872 | NI | ||
Male | 65.9% | ||||
Female | 66.2% | ||||
Age | 17.245 | 0.000 | 0.000 | ||
< 60 | 69.3% | Ref | |||
≥ 60 | 60.9% | 0.747 (0.654 ~ 0.866) | 0.000 | ||
Race | 17.535 | 0.000 | 0.625 | ||
White | 66.8% | Ref | |||
Black | 51.6% | 1.125 (0.880 ~ 1.436) | 0.347 | ||
Others | 71.3% | 1.767 (1.290 ~ 2.421) | 0.000 | ||
Grade | 41.722 | 0.000 | 0.000 | ||
Grade I/ II | 69.5% | Ref | |||
Grade III/ IV | 53.9% | 0.670 (0.566 ~ 0.794) | 0.000 | ||
Histologic type | 24.617 | 0.000 | 0.037 | ||
Adenocarcinoma | 67.4% | Ref | |||
Mucinous adenocarcinoma | 60.7% | 0.562 (0.378 ~ 0.836) | 0.004 | ||
Signet ring cell carcinoma | 41.8% | 0.588 (0.383 ~ 0.904) | 0.016 | ||
ypT stage | 66.241 | 0.000 | 0.000 | ||
1 | 73.0% | Ref | |||
2 | 83.7% | 0.442 (0.242 ~ 0.810) | 0.008 | ||
3 | 65.1% | 0.276 (0.195 ~ 0.391) | 0.000 | ||
4 | 46.8% | 0.564 (0.451 ~ 0.704) | 0.000 | ||
LNs | 1.975 | 0.160 | NI | ||
≤ 12 | 64.9% | ||||
> 12 | 67.0% | ||||
NLN | 33.138 | 0.000 | 0.000 | ||
≤ 9 | 60.5% | Ref | |||
> 9 | 71.4% | 1.466 (1.264 ~ 1.700) | 0.000 |